Nordic MDS-group

Introduction
Coordinators
Members
Studies
Publications
Diagnosis and prognosis
Nordic Care Programme
Meeting Calendar
Contact information

Patient informations

Danish 
Finish 
Icelandic 
Norwegian 
Swedish 

Members only

User name:  

Password:  

A multicenter phase II study of the efficacy and safety of lenalidomide in high-risk myeloid disease (high-risk MDS and AML) with a karyotype including del(5q) or monosomy 5.NMDSG07A

Read more

A Multicenter, randomized, double-blind, placebo-controlled, 2-arm study of the efficacy and safety of 2 doses of lenalidomide versus placebo in red blood cell (RBC) transfusion-dependent subjetcs with low -or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion (DEL) 5q[31] cytogenetic abnormality.

Read more

Maintenance treatment with Azacitidine in patients with advanced MDS and MDS-AML, who have obtained CR with intensive chemotherapy study (NMDSG02B).

Read more

Effects on anemia in MDS - Quality of life, cardiac funtion and health care costs (NMDSG03A). An open non-randomised phase II study.

Read more

A Multicenter, Randomised, Open-Label, Parallel-Group, Phase 3 Trial of Subcutaneous Azacytidine plus best supportive care versus conventional care regimens plus best supportive care for treatment of myelodysplastic syndromes (AZA PH GL 2003 CL 001).

Read more

Current news

August 2008, Newsletter NMDSG
[2008-08-19]
Administrative issues,
study issues and events...

Next NMDSG meeting
[2008-05-13]
will be held in
Stockholm, Nov 21-22

Meeting Minutes
[2008-05-13]
from the Nordic MDS
Group meeting
2008-04-25

Meeting agenda
[2008-04-24]
Welcome 25 April,
please see final agenda
(PDF document)

Invitation to meeting
[2008-03-06]
News, invitation to
meeting and information

Meeting Minutes
[2007-12-07]
from the Nordic MDS
Group meeting
2007-11-15-16